Kansas § 65-6b02 Same; use in treatment by physician, limitations on interference with

Kansas Statutes

§ 65-6b02 — Same; use in treatment by physician, limitations on interference with

Kansas § 65-6b02

Ch. 65PUBLIC HEALTH

Art. 6bAMYGDALIN (LAETRILE)

This text of Kansas § 65-6b02 (Same; use in treatment by physician, limitations on interference with) is published on Counsel Stack Legal Research, covering Kansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Kan. Stat. Ann. § 65-6b02 (2026).

Text

No medical care facility or other health care facility shall interfere with the physician-patient relationship by restricting or prohibiting the use of amygdalin (laetrile) as an adjunct to recognized, customary or accepted modes of therapy or by itself in the treatment of any malignancy, disease, illness or physical condition when amygdalin (laetrile) is prescribed or administered by a physician, and the patient has signed the written informed request therefor substantially as set forth in K.S.A. 65-6b05.

Free access — add to your briefcase to read the full text and ask questions with AI

No medical care facility or other health care facility shall interfere with the physician-patient relationship by restricting or prohibiting the use of amygdalin (laetrile) as an adjunct to recognized, customary or accepted modes of therapy or by itself in the treatment of any malignancy, disease, illness or physical condition when amygdalin (laetrile) is prescribed or administered by a physician, and the patient has signed the written informed request therefor substantially as set forth in K.S.A. 65-6b05.